Positive Phase II Data Support Entinostat Treatment for Advanced Breast Cancer

Entinostat is an inhibitor of class I histone deacetylase, an enzyme involved in epigenetic gene regulation commonly altered in cancers. Importantly, doctors can perform a simple test to determine whether or not entinostat will be effective in a patient shortly after it’s administration. For postmenopausal women with estrogen-receptor positive metastatic breast cancer, combining entinostat with exemestane resulted in a 27% reduction in risk of disease progression and increased the overall survival rate to 26.9 mths, compared to 20.3 mths for exemestane alone. In this study, researchers found that elevated levels of protein acetylation could predict which patients would benefit from entinostat treatment, as there was a 68% reduced risk for disease progression compared to patients who did not have elevated levels of protein acetylation. I like this approach because it targets multiple cancer causing mechanisms (epigenetic and hormonal), has minimal side effects compared to chemo/radiation therapy, has a predictive test to identify which patients will benefit and provides treatment options for metastatic breast cancer patients that have failed treatment with the nonsteroidal aromatase inhibitors anastrozole or letrozole.
Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks.

NEW! GENE TARGETED NUTRACEUTICAL DIET FOR ESTROGEN POSITIVE BREAST CANCERS NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*